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Serial passage of initially nonlethal Ebola virus (EBOV) in outbred guinea pigs resulted in the selection of variants with high
pathogenicity. Nucleotide sequence analysis of the complete genome of the guinea pig-adapted variant 8mc revealed that it
differed from wild-type virus by eight mutations. No mutations were identified in nontranscribed regions, including leader,
trailer, and intragenic sequences. Among noncoding regions the only base change was found in the VP30 gene. Two silent
base changes were found in the open reading frame (ORF) encoding NP protein. Nucleotide changes resulting in single-
amino-acid exchanges were identified in both NP and L genes. Three other mutations found in VP24 caused amino acid
substitutions, which are responsible for larger structural changes of this protein, as indicated by an alteration in electro-
phoretic mobility. A highly pathogenic EBOV variant K5 from another passaging series showed an amino acid substitution at
nearly the same location in the VP24 gene, suggesting the importance of this protein in the adaptation process. In addition,
sequence variability of the GP gene was found when plaque-purified clones of EBOV-8mc were analyzed. Three of five viral
clones showed insertion of one uridine residue at the GP gene-editing site, which led to a significant change in the expression
of virus glycoproteins. This observation suggests that the editing site is a hot spot for insertion and deletion of nucleotides,
not only at the level of transcription but also of genome replication. Irrespective of the number of uridine residues at the
editing site, all plaque-purified clones of EBOV variant 8mc resembled each other in their pathogenicity for guinea pigs,
indicating either the absence or only supportive role of mutations in the GP gene on the adaptation process. © 2000 Academic
Press
oINTRODUCTION
Ebola virus (EBOV) is an enveloped nonsegmented
negative-stranded RNA virus that belongs to the family
Filoviridae in the order Mononegavirales (Peters et al.,
1996; Feldmann and Kiley, 1999). Negatively contrasted
EBOV particles contain an electron-dense central core
formed by the ribonucleoprotein (RNP) complex, which is
surrounded by a lipid envelope derived from the host cell
plasma membrane. RNP complexes consist of genomic
RNA and the viral structural proteins VP30, VP35, nucleo-
protein (NP), and polymerase (L) protein. It was recently
demonstrated that the NP, VP35, VP30, and L proteins are
the minimal requirements for the efficient transcription
and RNA replication of an EBOV minigenome (Mu¨hl-
berger et al., 1999). Three other proteins (VP40, glyco-
protein [GP], and VP24) are membrane-associated. Ex-
cept for GP, which is encoded in two frames and ex-
pressed through transcriptional editing (Volchkov et al.,
1995; Sanchez et al., 1996), all EBOV proteins are en-
Sequence data reported in this article have been deposited in the
GenBank database under Accession No. AF272001.
1 To whom correspondence and reprint requests should be ad-
dressed at University Claude Bernard Lyon-1, Filovirus Laboratory, 21
avenue Tony Garnier, 69365 Lyon Cedex 07, France. Fax: 133-472-
728777. E-mail: Viktor.Volchkov@ens-lyon.fr.
147coded in single reading frames (Volchkov et al., 1992;
Sanchez et al., 1993). Mature surface GP1,2 is a complex
f the subunits GP1 (140 kDa) and GP2 (26 kDa) that are
linked by a disulfide bond. Cleavage of precursor GP
occurs during intracellular transport by subtilisin-like en-
doproteases, most likely furin (Volchkov et al., 1998,
1999a). A nonstructural small glycoprotein sGP is ex-
pressed from nonedited GP mRNA and efficiently se-
creted from infected cells as a homodimer in antiparallel
orientation (Volchkova et al., 1998). Mature sGP is also
proteolytically cleaved by furin, and cleavage results in
the release of a short carboxyl-terminal glycopeptide
(D-peptide) into the culture medium (Volchkova et al.,
1999).
Ebola hemorrhagic fever (HF) is the most severe form
of viral HF associated with hemorrhagic manifestations,
marked hepatic involvement, coagulation disorders, gen-
eralized shock, and the highest case-fatality rate (Peters
et al., 1996; Schnittler and Feldmann, 1999). The primary
target of EBOV appears to be the mononuclear phago-
cytic system (MPS), but as the virus spreads through the
organism the spectrum of target cells increases to in-
clude endothelial cells, fibroblasts, and hepatocytes
(Fisher-Hoch et al., 1985; Geisbert and Jahrling, 1995;
Ryabchikova et al., 1996; Bray et al., 1999). Filovirus-
induced massive apoptosis of peripheral lymphocytes
0042-6822/00 $35.00
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148 VOLCHKOV ET AL.was recently documented in vitro and in vivo during
nfection by Ebola and Marburg viruses (Baize et al.,
999; Geisbert et al., 2000).
Guinea pigs are a suitable animal system for the
solation of filoviruses. Animals inoculated with EBOV
btained from primates normally develop a nonlethal
ebrile illness. However, serial passage in these animals
esults in a substantial increase in lethality (Bowen et al.,
980; Chepurnov et al., 1995; Ryabchikova et al., 1996).
he pathomorphological changes that occur during con-
ersion from nonlethal to lethal infection were studied
reviously by light and electron microscopy (Ryab-
hikova et al., 1996; Connolly et al., 1999). The molecular
basis for the increase in virulence, however, is unknown.
Here we demonstrate that the guinea pig-adapted
variant 8mc of EBOV differed from wild-type virus by
mutations in the coding regions of NP, VP24, and L-
polymerase genes, and by one mutation in the noncod-
ing region of the VP30 gene. A VP24 mutation was found
at nearly the same location in EBOV variant K5, obtained
from another passaging series, thus leading to specula-
tion on the importance of this protein for host adaptation
and increase in pathogenicity. In addition, an insertion of
a single uridine residue at the GP gene-editing site was
observed with three out of five plaque-purified viral
clones of variant 8mc, which led to substantial changes
in the expression strategy of the GP gene.
RESULTS
Molecular characterization of guinea pig-adapted
EBOV variants
To determine the changes in the viral genome asso-
ciated with adaptation to guinea pigs, variant 8mc was
subjected to complete nucleotide sequence analysis.
Prior to sequence determinations five individual plaque-
purified viral clones of EBOV-8mc were isolated and
examined for their pathogenicity in guinea pigs. All five
clones showed increased virulence for guinea pigs over
that of wild-type virus (Table 1). The PFU/LD50 ratios
were similar, with all 8mc clones indicating that the
variations in the LD50 titers can be explained by differ-
ences in the amount of virus used for infection. The
primary structure of the full-length genomic RNA of EBOV
was previously determined (GenBank Accession No.
AF086833) (Volchkov et al., 1999b). Based on this se-
quence a set of primers was designed to generate a
number of PCR fragments covering the complete ge-
nome of EBOV (Table 2). The complete nucleotide se-
quence of clone N4 of EBOV-8mc was determined by
sequencing the RT-PCR fragments (GenBank Accession
No. AF272001) and then compared with the sequence of
original wild-type EBOV. Nucleotide substitutions and
amino acid exchanges found in clone N4 are shown in
Table 3. The same mutations, the only exception of which
was the GP gene, were also found in the other fourclones of EBOV-8mc. One base change was found in the
noncoding region of the VP30 gene. No mutations were
identified in nontranscribed regions, including leader,
trailer, and intragenic sequences. Two silent base
changes were found in the ORF encoding the NP protein.
ORFs encoding proteins VP35 and VP40 did not show
any mutations compared with those of the parental virus.
The NP and L-polymerase genes each revealed a single
nucleotide change, leading to amino acid substitution
Phe 3 Leu648 and Thr 3 Ala820, respectively. Three nu-
cleotide changes were found in the coding region of the
VP24 gene, which all led to amino acid substitutions
(Met 3 Ile71, Leu 3 Pro147, and Thr 3 Ile187). The 8mc
lones showed, in total, eight common sequence
hanges when compared to those of wild-type EBOV.
equence variability among plaque-purified clones of
BOV-8mc was observed only in the GP gene. Clones
1, N4, and N5 contained an additional uridine residue
genomic sense) inserted at the GP gene-editing site and
lso a mutation at position 7228 (U 3 C), leading to
mino acid substitution Asp 3 Gly397. Two other viral
clones (N2 and N3) showed no differences in their GP
gene compared with wild-type EBOV (Table 3), and there-
fore seven uridine residues were present at the GP
gene-editing site.
When wild-type and EBOV-8mc were analyzed by
SDS–PAGE no differences in protein composition and
migration mobility were observed, except for the mem-
brane-associated protein VP24. VP24 of EBOV-8mc mi-
grated more slowly than VP24 from wild-type virus (Fig.
1). A similar difference in migration patterns was ob-
served when both proteins were expressed in vitro using
a coupled transcription/translation T7 RNA polymerase
system, indicating that at least one of the three identified
substitutions was responsible for an alteration in the
conformation of VP24 (data not shown). These data sug-
gest that the mutations in VP24 play a crucial role in the
TABLE 1
Titers in the Liver of Guinea Pigs Inoculated with Five Plaque-
Purified Clones of EBOV-8mc
Clonea log10 LD50 log10 PFU/ml
1 (8U) 4.25 6 0.4 3.9 6 0.3
2 (7U) 5.5 6 0.3 4.1 6 0.5
3 (7U) 5.25 6 0.3 5.1 6 0.3
4 (8U) 5.5 6 0.4 4.95 6 0.4
5 (8U) 6.5 6 0.5 6.1 6 0.3
wt (7U) 1.0 6 0.3 5.0 6 0.3
Note. The biological activity of EBOV was determined on Day 6
postinoculation by titration on guinea pigs (LD50) or on Vero cells
(plaque assay). LD50, lethal dose; PFU, plaque-forming units.
a Number of uridine residues at the GP gene-editing site is indicated
n parentheses.adaptation process.
To prove this hypothesis and also to get additional
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149GUINEA PIG-ADAPTED VARIANTS OF EBOVinformation on the process of EBOV adaptation, we per-
formed an independent series of EBOV passages in
adult guinea pigs. The passage history of the primary
virus used in this series was different from that of the
variant from which 8mc had been obtained. This virus
(EBOV subtype Zaire, strain Mayinga) had been pas-
saged three times in monkeys followed by 15 passages
T
Oligonucleotide Primers Used in RT-PCR to Generate a N
Primer Target Prim
1 39-end 59-TTTGAATTCC
2 NP 59-GGATCTTTTG
3 NP 59-TCTTGTGGTA
4 NP 59-CTCGGAATC
5 NP 59-CATTGAAGAC
6 VP35 59-TGAAGATTAA
7 VP35 59-TTGCTCAACG
8 VP40 59-AGAAAAACC
9 VP40 59-GCTCACTGTC
10 GP 59-TCGGGACCC
11 GP 59-CGTGTCCATC
12 VP30 59-ATCAGATCTG
13 VP30 59-TCGTTGTAGG
14 VP24 59-CGCCACAAA
15 VP24 59-CTTGGTAACA
16 L 59-GAAGCAGTT
17 L 59-GTGTGCGAC
18 59-end 59-GTAAAATAAG
Note. The nucleotide enumeration is as in GenBank Accession No.
[
[
[
[
[
[
[
[
TABLE 3
Nucleotide and Amino Acid Changes in Wild-Type and
Giunea Pig-Adapted EBOV-8mc
Viral proteins Changed nucleotides Changed amino acids
NP 1852 (C3 U) —
2410 (U3 C) —
2411 (U3 C) 648 (Phe3 Leu)
VP35 — —
VP40 — —
GPa 6924 (insertion) ORF shift
7228 (A3 G) 397 (Asp3 Gly)
VP30b 9595 (U3 A) —
VP24 10557 (G3 A) 71 (Met3 Ile)
10784 (U3 C) 147 (Leu3 Pro)
10904 (C3 U) 187 (Thr3 Ile)
L 14038 (A3 G) 820 (Thr3 Ala)
Note. The reference nucleotide sequence included in the analysis
was EBOV, subtype Zaire, strain Mayinga (GenBank Accession No.
AF086833).
a EBOV-8mc showed variability at the GP gene. Three of the five
laque-purified viral clones contained an additional uridine residue at
he editing site (see Table 1) and a nucleotide substitution at position
228. The insertion led to the open reading frame shift (Volchkov et al.,E
s
995).
b Mutation is located in the 39-end noncoding region of VP30 mRNA.on human lung L68 cells before guinea pig adaptation.
The adult guinea pigs showed a higher resistance to
EBOV infection than did young animals used when
EBOV-8mc was generated (Chepurnov et al., 1995). Pas-
sage numbers one and two in adult animals resulted in
very mild or even asymptomatic disease, which was in
sharp contrast to adaptation performed in young guinea
pigs where lethal outcome was already observed after
the first passage. Only three animals (passage one) and
FIG. 1. SDS–PAGE analysis of variant 8mc. Vero cells were infected
with either EBOV wild-type or guinea pig-adapted EBOV variant 8mc
(m.o.i. of 1022). Culture medium was harvested 5 days postinfection,
nd virus was purified through a sucrose density gradient as described
reviously (Chepurnov et al., 1994; Feldmann et al., 1991). After purifi-
ation viruses were analyzed on 12.5% SDS–polyacrylamide gels.
of PCR Fragments Covering Complete Genome of EBOV
uence (sense) Primer position
AAATTTCAATGAG (2) 78–101
GAATAAC (1) 31–52
TGTC (2) 521–539
ATTCCGAGTATGG (1) 447–473
GCTTCGAGTGCTAG (2) 3076–3104
TCATCATCCTTACGTC (1) 3034–3064
AAGATGAAGGTTAATG (2) 4435–4465
CGGCTGAGAGAGT (1) 4401–4427
TAATCTTCATC (2) 5900–5924
TAGGTTGTTCACA (1) 5830–5856
GAATGCTGTC (2) 8549–8573
CCGGTAGAGTTT (1) 8406–8431
CTTCTTTTCAGCCAA (2) 10175–10203
CTCTAAGC (1) 10039–10060
ATCGTATTTC (2) 11738–11763
TCTTCCTCTTG (1) 11549–11573
TTCCAGGAATC (2) 18892–19016
AGGTG (1) 18677–18696
33.ABLE 2
umber
er seq
GATAT
TGTGC
ATCCA
ACAAA
AATAA
AACCT
TTTAC
TACCT
GGCT
ATTTC
CCTT
CGAA
TAAG
AGTGT
GTTAC
GAAAT
CATTT
AGATTBOV glycoprotein GP usually is not fully visible after Coomassie
taining of SDS–PAGE gels.
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150 VOLCHKOV ET AL.five (passage two) from groups of 15 showed a rise in
temperature, whereas all others did not develop detect-
able disease symptoms within 20 days postinfection
(p.i.). During the following passages lethality increased
and peaked at passage five. Interestingly, virus titers in
the liver of animals were very similar during all passages
when determined by plaque test (plaque-forming units
[PFU]/ml), but LD50 or ID50 titers markedly increased
during adaptation (Table 4). First deaths were noticed on
passage three, and on passage five all inoculated ani-
mals had already developed lethal disease. Similarly to a
previous adaptation series (Chepurnov et al., 1995), we
ere not able to detect virus in the blood of animals after
he first passage, although animals inoculated with the
iver homogenates showed a rise in temperature on
ays 5 and 6 p.i. Relatively high virus titers in the liver
omogenates (Table 4) and nondetectable virus titers in
lood suggest that liver is the major organ in which virus
eproduction occurs, at least during the first passages. In
ate passages, however, virus was also detected in the
lood, reaching titers of approximately 105 PFU/ml.
The virus obtained after five passages in this series
was plaque-purified and designated EBOV variant K5
(EBOV-K5). Comparative nucleotide sequence analysis of
the region coding for VP24 revealed two nucleotide ex-
changes between EBOV strain Mayinga and EBOV-K5,
leading to amino acid substitutions Asp 3 Gly165 and
His 3 Tyr186. The mutation at position 165 had already
been introduced during passage of EBOV either in mon-
keys or most probably on L68 cells, because it was also
observed in the initial virus stock used for guinea pig
adaptation. This mutation, therefore, was not responsible
TABLE 4
Titers of EBOV in the Liver of Infected Guinea Pigs
during Serial Passage
Passage log10 LD50 log10 ID50 log10 PFU/ml
1 0 2.5 4.4
2 0 3.0 4.3
3 0.5 3.6 4.5
4 3.6 5.8 4.7
5 5.7 7.0 4.8
6 5.7 7.0 4.7
7 5.8 6.9 4.6
Note. Guinea pigs (250–300 g) were infected intraperitoneally with 1
3 105 PFU of EBOV, subtype Zaire, strain Mayinga, that was additionally
passaged 15 times in the L68 cell line. Serial passages in guinea pigs
were carried out by infection of animals with 1 ml of a 10% suspension
of livers from previous passages. LD50 and ID50 of EBOV were deter-
mined on Day 6 postinoculation by titration on guinea pigs. Plaque
assays were done on Vero cells. The PFU, LD50, and ID50 values were
obtained by the method of Spearman-Kaerber (Brown et al., 1961). Virus
from passage five was propagated on Vero E6 cells and designated as
EBOV-K5.for the increase in guinea pig pathogenicity observed in
Table 4. However, the mutation His 3 Tyr186 was intro-uced during the guinea pig passages. Sequence anal-
sis of the VP24 gene in all intermediate virus passages
howed that this mutation occurred after passage num-
er three, concomitantly with the change in virulence.
nterestingly, this substitution is located almost at the
ame position as one of the mutations found with the
BOV variant 8mc (Thr 3 Ile187). It should be noted that
he difference in LD50 between virus stocks of passage
umber three and the previous passages was relatively
mall, although pathogenicity increased significantly af-
er one additional passage (Table 4). This discrepancy
ould be explained, at least in part, by the fact that virus
sed for sequence determination was passaged one
dditional time on Vero cells, whereas liver homoge-
ates from infected guinea pigs had been used immedi-
tely for LD50 determinations.
BOV-8mc RNA editing pattern
The insertion of one uridine residue at the editing site
f the EBOV GP gene (seven consecutive uridine resi-
ues, genomic sense) found in the genomic RNAs of
hree clones of EBOV-8mc (eight uridine residues) per-
its synthesis of surface glycoprotein GP1,2 without the
eed of RNA editing. Simultaneously with the opening of
he reading frame encoding GP1,2, the insertion elimi-
nates the ORF coding for sGP and should therefore
theoretically prevent synthesis of sGP. Analysis of the
culture supernatants from Vero cells infected with EBOV-
8mc (clone N4), however, showed that sGP is synthe-
sized (Fig. 2), although the expression rate is significantly
reduced compared with that in wild-type infection. Sup-
ported by previous observations, which indicate that
eight uridine residues are recognized as an editing site
in recombinant expression systems (Volchkov et al.,
1995), these data suggested that RNA editing is also the
mechanism of sGP synthesis in the case of EBOV-8mc.
To further assess whether replication of EBOV variants
containing eight uridine residues involves editing and
also to determine the extent of editing, total mRNA was
isolated from Vero E6-infected cells and transcribed into
cDNA, and GP gene-specific cDNA was amplified by
PCR. PCR fragments were cloned into the vector
pGEM3Zf(1), and 179 clones were analyzed by sequenc-
ing. As shown in Fig. 2, multiple editing products were
detected with up to two deleted and up to seven inserted
adenosine residues at the GP gene-editing site (mRNA
sense). In contrast to wild-type virus, which yielded 80%
of GP gene-specific mRNAs coding for sGP and 20% for
GP (Volchkov et al., 1995), approximately 76% of the GP
gene-specific mRNAs of EBOV-8mc encoded full-length
GP1,2 and only 9.5% sGP. Because of multiple deletions or
insertions of adenosine residues at the editing site, a
number of GP gene-specific proteins differing in the
amount of Lys residues following position 295 should
also be synthesized. This is also the case when tran-
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151GUINEA PIG-ADAPTED VARIANTS OF EBOVscription is driven by T7- or vaccinia virus-specific RNA
polymerases (Volchkov et al., 1995). Transcripts with 6, 9,
2, or 15 adenosine residues result in an open reading
rame (ORF) terminated just downstream of the editing
ite. This reading frame directs synthesis of the third GP
ene-specific product ssGP, which shares the NH2-ter-
minal region with GP and sGP, but differs at the COOH-
terminus by utilizing a third reading frame (Volchkov et
al., 1995; Volchkova et al., 1998). Similar to sGP, it lacks
the membrane anchor and is thus secreted from cells. It
was difficult to distinguish sGP and ssGP on SDS–PAGE
gels because both proteins migrated as very diffuse
bands. Better discrimination was achieved after treat-
ment with PNGase F, which removed all N-linked sugars
from the proteins (Fig. 3). The detection of edited GP
gene-specific mRNAs in infected Vero cells and the iden-
FIG. 2. Frequency of editing of EBOV GP mRNA. Vero-E6 cells were
ulture medium was harvested 5 days postinfection. Proteins were a
mmunoglobulins (1:3000). The entire ORF of the EBOV GP gene was o
lone 4, by the PCR technique as described previously (Volchkov et al.
equencing of plasmid clones. A total of 179 cDNA clones derived from
previous publication (Volchkov et al., 1995). Abbreviations of the pro
FIG. 3. Expression and release of nonstructural glycoproteins. Vero
ells were infected with either wild-type EBOV or variant 8mc (m.o.i. of
022). Culture medium was harvested 5 days postinfection. After clear-
ance of viral particles from medium by ultracentrifugation, culture
supernatants were divided in two parts and analyzed on 10% SDS–
polyacrylamide gels prior to or after PNGase F digestion. Detection of
GP-specific proteins was performed with goat anti-EBOV immuno-E
globulins. Fivefold more material of EBOV-8mc than of wild-type EBOV
were applied.tification of both nonstructural glycoproteins, sGP and
ssGP, in the culture supernatants finally confirmed that
transcriptional RNA editing occurs during replication of
this variant of EBOV.
DISCUSSION
Comparative sequence analysis of the complete ge-
nome of wild-type EBOV and the guinea pig-adapted
variant EBOV-8mc showed eight common nucleotide dif-
ferences, which led to five amino acid substitutions,
including two mutations in both NP and L proteins and
three in VP24. Two silent nucleotide mutations were
identified in the NP gene and one mutation was found in
the noncoding region of the VP30 gene. Silent mutations
in NP obviously reflect variability of EBOV at the level of
genomic RNA that clearly do not affect the functionality of
this protein. The mutation in the VP30 gene appears to
be nonfunctional as well, since it is located in the 39-end
noncoding region. Two other nucleotide substitutions in
NP and L genes resulted in single-amino-acid ex-
changes of a conservative nature. However, one cannot
conclude unambiguously that these mutations are not
important for the increase in virulence, because they
were present in all five plaque-purified viral clones of
EBOV-8mc and because even single conservative sub-
stitutions may have effects on virus replication. Recently,
for example, it was demonstrated that introduction of a
single Phe 3 Leu substitution in the L protein of respi-
atory syncytial virus (RSV) led to a temperature-sensitive
henotype and to attenuation of this virus (Juhasz et al.,
997). Further studies, including reverse genetic experi-
ents, are necessary to clearly determine the functional
ignificance of all amino acid substitutions identified in
P and L genes.
d with wild-type EBOV and EBOV variant 8mc, clone 4 (m.o.i. of 1022).
d following 10% SDS–PAGE by immunoblotting using goat anti-EBOV
from mRNA isolated from Vero cells infected with EBOV variant 8mc,
The primary structure at the GP gene-editing site was determined by
mc mRNA were analyzed. Data for wild-type EBOV were obtained from
ducts are indicated in parentheses.infecte
nalyze
btained
, 1995).The finding that the independently obtained variants
BOV-8mc and EBOV-K5 showed mutations in VP24 at
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152 VOLCHKOV ET AL.positions immediately adjacent to each other (His 3
Tyr186 and Thr 3 Ile187, respectively) supports the notion
hat these amino acid exchanges are important for virus
daptation to guinea pigs. It is also interesting that the
utations in VP24 are responsible for large structural
hanges, as indicated by an alteration in the electro-
horetic mobility of this protein in SDS–PAGE gels. The
utation at position 165, which appeared most likely
uring passages of EBOV on L68 cells, does not lead to
change in virulence for guinea pigs, although it may
lay a role in the adaptation of the virus to the new host.
Serial passage of viruses either in animals or cell
ultures frequently results in the selection of mutants
hat have reproduction advantages over those of wild-
ype virus (Kissi et al., 1999; Gubareva et al., 1994;
Tashiro et al., 1988). Depending on the selection mode,
viruses with lower or higher virulence have been ob-
tained in adaptation experiments. Several examples are
known where changes in virulence were directly linked
to the efficiency of virus assembly and/or release from
infected cells (Tashiro et al., 1988; Cattaneo et al., 1989;
Baczko et al., 1991). Interestingly, changes in the struc-
ure of the membrane-associated protein M have been
ound to be associated with a shift in the pathogenicity of
endai virus (Tashiro et al., 1996), resembling the obser-
ation made here on VP24. The mutated M protein was
ound to be involved in an enhanced disruption of the
icrotubule network, leading to impairment of cellular
olarity, bipolar budding of the virus, and systemic infec-
ion in mice (Tashiro et al., 1988). The mutated protein
ad two amino acid substitutions that also caused ab-
ormal migration in SDS–PAGE. Single-amino-acid mu-
ations in the matrix protein of measles virus have also
een shown to reduce the amount of M protein and,
herefore, the efficiency of virus release from infected
ells (Rima et al., 1995).
At present mutations in VP24 are the only ones that
can be linked to the changes in virulence. However, the
functional significance of the mutations in VP24 is not yet
understood. Amino acid sequence analysis of VP24 re-
vealed a strong hydrophobic character, suggesting mem-
brane association, a concept supported also by the ob-
servation that VP24 and the envelope glycoprotein GP
are easily removed from the RNP complex by detergent
treatment (Elliott et al., 1985). It is reasonable to assume
that VP24 may interact with GP and/or with cellular mem-
branes and play a role during virus assembly and re-
lease from infected cells. Since it interacts with GP it may
also be involved in the determination of the range of
target cells. It has previously been shown that, in addi-
tion to liver macrophages, several other cell types, such
as hepatocytes, fibroblasts, and endothelial cells, are
involved in virus reproduction during sequential passag-
ing of EBOV in guinea pigs (Ryabchikova et al., 1996).The variations in the GP gene of the plaque-purified
clones of EBOV-8mc are also of considerable interest.Three of the five analyzed viral clones had GP mutations
that resulted in an amino acid change at position 397
and in the insertion of a uridine residue at the editing
site. Although the GP mutations were not observed with
all of the EBOV-8mc clones and, thus, do not seem to
play an essential role in the increase in lethality, they
nevertheless may be supportive in the process of adap-
tation. Insertion of the uridine residue drastically alters
the expression strategy of the GP gene. Whereas sGP is
the dominant expression product with wild-type virus
and GP is synthesized in smaller amounts, the propor-
tions are inverted with EBOV-8mc. Furthermore, the in-
sertion of the additional uridine residue substantially
changed the efficacy and accuracy of editing compared
with that of wild-type virus. Several GP gene-specific
proteins not observed with wild-type virus were synthe-
sized with EBOV-8mc, one of which is ssGP that was
previously observed only in recombinant expression sys-
tems (Volchkov et al., 1995; Volchkova et al., 1998). Be-
cause of the cleavage of sGP by subtilisin-like cellular
endoproteases and the release of D-peptide, which com-
prises the 40 carboxyl-terminal amino acids, there is only
a small difference in size (27 a.a.) between sGP and
ssGP (Volchkova et al., 1999). Although sGP and ssGP
are almost identical in their primary structures, they differ
in oligomerization patterns. Since ssGP does not contain
the Cys residue at position 362, which was shown to be
required for the dimerization of sGP, it is synthesized and
secreted from cells as a monomer (Volchkova et al.,
1998). The function of ssGP still has to be determined.
Previous sequence analysis of the genomic RNA of
EBOV did not show variability at the GP gene-editing site.
The insertion of a uridine residue found in genomic RNA
of plaque-purified EBOV-8mc indicates that editing oc-
curs not only during transcription but also at the level of
genome replication, most likely when positive-strand
copies of the viral genome are synthesized. The mech-
anism of editing seems to be similar to that suggested
previously for transcriptional editing of GP mRNA. Tem-
porary pausing of the viral RNA polymerase at the editing
site enables the replicase complex to slip backward and
forward on the vRNA template before the next nucleotide
is incorporated. It appears that editing at the genomic
level is a relatively rare event that can be detected
occasionally either after analysis of individual plaque-
purified viral clones (Volchkov et al., 1995; Sanchez et al.,
1996; Calain et al., 1999) or after selection of variants
during adaptation to guinea pigs.
Interestingly, the genomes of wild-type EBOV and
guinea pig-adapted EBOV-8mc, clone N4, differ in size by
only one nucleotide (18959 and 18960 nucleotides, re-
spectively). No other insertions or deletions have been
found with this EBOV-8mc clone which could eliminate
this difference. These data confirm a previous observa-
tion made on minireplicons of EBOV (Calain et al., 1999),
indicating that the length of artificial genomic RNAs may
g
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ficiency and that no obvious genome length rule, such as
“the rule of six” found for several members of the
Paramyxoviridae family (Calain and Roux, 1993; Durbin et
al., 1997), is applicable to the filoviruses.
This study is the first attempt to identify regions and
genes of EBOV, which might be responsible for the in-
crease in virus pathogenicity that occurs during serial
passage of the virus in guinea pigs. The molecular mech-
anism underlying the shift in pathogenicity is still not
clear. However, the finding that variant EBOV-8mc dif-
fered from wild-type virus by only eight mutations in the
NP, VP30, VP24, and L genes substantially narrowed the
field on which further investigations have to focus.
MATERIALS AND METHODS
Generation of EBOV variant K5
To generate EBOV variant K5, EBOV subtype Zaire,
strain Mayinga, was used. This virus was received from
the Institute of Microbiology and Epidemiology (Minsk,
Belorussia) and was passaged 24 times in Vero E6 cells.
In addition, this virus was passaged three times in mon-
keys followed by 15 passages in L68 cells (a human
embryonic lung cell line) before guinea pig adaptation
experiments. Serial passage of EBOV in guinea pigs was
performed as described (Chepurnov et al., 1995). Guinea
pigs (250–300 g) were initially inoculated intraperitone-
ally (i.p.) with 1 3 105 PFU of EBOV per animal. After 6
days, only animals that showed a rise in rectal temper-
ature (from 38.5–39.0 to 40–42°C) were killed; the livers
were then aseptically removed and pooled. For the fol-
lowing passages animals were inoculated with 1 ml of a
10% liver homogenate from animals showing a rise in
temperature on Day 6 postinoculation (p.i.). Prior to se-
quence analysis, the virus was passaged once on Vero
E6 cells. Culture supernatants were harvested 5 days
after virus inoculation; the virus was then pelleted by
ultracentrifugation and genomic RNA was isolated using
a commercial kit (RNAeasy Kit; Qiagen, Germany) ac-
cording to the manufacturer’s instructions. Virus ob-
tained after five guinea pig passages was plaque-puri-
fied in Vero E6 cells.
EBOV variant 8mc
In this case, EBOV subtype Zaire, strain Zaire, was
used for guinea pig passages. The passage history of
this virus, prior to guinea pig passages, was previously
described (Chepurnov et al., 1995), and its complete
genome sequence was found to be identical to that of
strain Mayinga (unpublished observation). Similarly to
EBOV-K5, EBOV variant 8mc (EBOV-8mc) was obtained
by eight consecutive guinea pig passages. EBOV-8mc
was purified by three consecutive plaque passages in
Vero E6 cells and was subsequently passaged threetimes in the same cells. A total of five clones of EBOV-
8mc were subjected to sequence and pathogenicity
analyses.
All Ebola viruses were cultured in Vero E6 cells and
purified from the tissue culture liquid as described pre-
viously (Chepurnov et al., 1994; Feldmann et al., 1991;
Volchkov et al., 1998). The Vero E6 and L68 cell lines
were maintained in Dulbecco’s medium containing 10%
fetal bovine serum (GIBCO, Germany).
Pathogenicity analysis
To examine the LD50 of EBOV, guinea pigs (250–300 g)
were infected i.p. (1 ml) with serial 10-fold dilutions of a
10% liver homogenate. After infection animals were kept
under isolation conditions for a maximum of 20 days.
Since virus of passage one did not lead to death, infec-
tivity titers (ID50) were determined instead by analyzing
the rise in rectal temperature on Days 5 and 6. ID50 is
the virus dilution causing an increase in temperature on
Day 6 p.i. in 50% of animals.
Titration by plaque test and plaque purification
Virus stocks or 10% liver homogenates of infected
animals were serially diluted in Dulbecco’s medium, ab-
sorbed onto confluent Vero E6 cells in 12-well dishes,
incubated for 1 h at 37°C, and covered with an agar
overlay. A 1:5000 dilution of neutral red in buffered saline
solution was added 6 days later, and plaques were
counted the following day.
For plaque purification, Vero E6 cells were infected
with diluted virus stocks and covered with agar overlay.
After staining with neutral red, single plaques were re-
moved with a pipet, suspended by freeze-thawing and
vortexing, and used to infect Vero E6 cells. Three se-
quential cycles of plaque purification were performed.
Plaque-purified viruses were amplified on Vero E6 cells,
stored in aliquots, and used in subsequent experiments,
including sequence analysis.
Molecular cloning and sequencing
Vero E6 cells were infected with plaque-purified
clones of EBOV-8mc at an m.o.i. of 1022 PFU/cell, and
virus purification was performed as previosuly described
(Chepurnov et al., 1994; Feldmann et al., 1991). Viral
enomic RNA was isolated using a commercial kit
RNAeasy Kit) according to the manufacturer’s instruc-
ions.
For first-strand cDNA synthesis, 5 mg of purified viral
RNA was used and reverse transcription was carried out
with random primers. Amplification of gene-specific frag-
ments by PCR was done using a set of EBOV-specific
oligonucleotide primers (Table 2). PCR products were
gel-purified (Gel Extraction Kit; Qiagen) and sequenced
using a cycle-sequencing protocol based on the chain
termination method on an automated DNA sequencer
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154 VOLCHKOV ET AL.(ABI 377; Applied Biosystems, Germany). The terminal
trailer region was determined by sequencing of specifi-
cally primed preparative cDNA essentially as described
previously (Volchkov et al., 1999b). The terminal leader
equence was determined using polyadenylation of the
9-end of viral RNA and subsequent RT-PCR. Briefly, 1 mg
f viral RNA was incubated for 30 min at 37°C in a 50-ml
reaction mix containing 5 units of poly(A) polymerase
(Amersham Pharmacia Biotech, Germany), 40 mM Tris
(pH 8.0), 10 mM MgCl2, 2.5 mM MnCl2, 250 mM NaCl, 250
mM ATP, and 50 mg of bovine serum albumin per ml.
T-PCR was done using an oligo (dT)21 primer containing
a BamHI site and a genome sense primer from the NP
gene (59-TTTGAATTCCGATATAAATTTCAATGAG, comple-
mentary to nucleotides 78 to 101) containing an EcoRI
site. A fragment of about 120 bp was cloned into pBlue-
script II KS1, and the leader consensus sequence was
etermined from four individual clones. The entire open
eading frame of the EBOV GP gene was obtained from
RNA isolated from EBOV-infected cells by the PCR
echnique as described previously (Volchkov et al., 1995).
The nucleotide sequence of the editing-site region was
determined using primers 59-GAGGTTGACAATTTGAC-
CTACG (genomic RNA (1) sense, nucleotides 6741 to
6762) and 59-TCGTGGCAGAGGGAGTGT (complementary
to nucleotides 7294 to 7311, genomic RNA (1) sense).
SDS–PAGE analysis, glycosidase (PNGase F)
treatment, and immunoblotting analysis
SDS–polyacrylamide gel electrophoresis (SDS–PAGE)
was carried out on high-resolution SDS-slab gels con-
taining 10 or 12.5% polyacrylamide, with a 4% stacking
gel, using the discontinuous buffer system of Laemmli
(1970). Virion proteins were visualized by staining with
Coomassie brilliant blue. Treatment of sGP with PNGase
F was performed according to the supplier’s instructions
(BioLabs, U.K.). Immunoblot analysis using anti-EBOV
goat immunoglobulins was carried out as described pre-
viously (Volchkov et al., 1995).
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